Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al
- PMID: 34212484
- DOI: 10.1111/dom.14485
Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al
Comment on
-
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.Diabetes Obes Metab. 2021 Jul;23(7):1594-1603. doi: 10.1111/dom.14373. Epub 2021 Mar 29. Diabetes Obes Metab. 2021. PMID: 33710717 Free PMC article. Clinical Trial.
-
Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.Diabetes Obes Metab. 2021 Oct;23(10):2411-2413. doi: 10.1111/dom.14473. Epub 2021 Jul 16. Diabetes Obes Metab. 2021. PMID: 34169640 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
